Search results for "kinases"

showing 10 items of 929 documents

EMBER—Embedding Multiple Molecular Fingerprints for Virtual Screening

2022

In recent years, the debate in the field of applications of Deep Learning to Virtual Screening has focused on the use of neural embeddings with respect to classical descriptors in order to encode both structural and physical properties of ligands and/or targets. The attention on embeddings with the increasing use of Graph Neural Networks aimed at overcoming molecular fingerprints that are short range embeddings for atomic neighborhoods. Here, we present EMBER, a novel molecular embedding made by seven molecular fingerprints arranged as different “spectra” to describe the same molecule, and we prove its effectiveness by using deep convolutional architecture that assesses ligands&…

Settore ING-INF/05 - Sistemi Di Elaborazione Delle InformazioniBinding SitesMolecular StructureDeep learning Drug design Embedding Virtual screeningResearchOrganic ChemistryGeneral MedicineLigandsCatalysisComputer Science ApplicationsInorganic ChemistryCDC2 Protein KinaseDrug DiscoveryMass Screeningdeep learning; drug design; virtual screening; embeddingNeural Networks ComputerPhysical and Theoretical ChemistryProtein KinasesMolecular BiologySpectroscopy
researchProduct

RNAi mediated acute depletion of Retinoblastoma protein (pRb) promotes aneuploidy in human primary cells via micronuclei formation

2009

BACKGROUND: Changes in chromosome number or structure as well as supernumerary centrosomes and multipolar mitoses are commonly observed in human tumors. Thus, centrosome amplification and mitotic checkpoint dysfunctions are believed possible causes of chromosomal instability. The Retinoblastoma tumor suppressor (RB) participates in the regulation of synchrony between DNA synthesis and centrosome duplication and it is involved in transcription regulation of some mitotic genes. Primary human fibroblasts were transfected transiently with short interfering RNA (siRNA) specific for human pRb to investigate the effects of pRb acute loss on chromosomal stability. RESULTS: Acutely pRb-depleted fibr…

Small interfering RNAMitosisCell Cycle ProteinsProtein Serine-Threonine KinasesRetinoblastoma ProteinAurora KinasesRNA interferenceChromosomal InstabilityProto-Oncogene ProteinsChromosome instabilitymedicineHumansCentrosome duplicationRNA Small Interferinglcsh:QH573-671MitosisCells CulturedCell NucleusCentrosomebiologylcsh:CytologyRetinoblastomaRetinoblastoma proteinCell BiologyFibroblastsAneuploidymedicine.diseaseCell biologyCentrosomeRNAi Aneuploidy pRBRb anauploidybiology.proteinRNA Interferencebiological phenomena cell phenomena and immunityResearch ArticleBMC Cell Biology
researchProduct

Post-Transcriptional Regulation of Human Inducible Nitric-Oxide Synthase Expression by the Jun N-terminal Kinase

2007

Human inducible nitric-oxide synthase (iNOS) expression is regulated both at transcriptional and post-transcriptional levels. In the present study, the effect of Jun N-terminal kinase (JNK) on human iNOS expression was investigated. In A549/8 human alveolar epithelial cells, both the inhibition of JNK by a pharmacological inhibitor anthra[1,9-cd]pyrazol-6(2H)-one1,9-pyrazoloanthrone (SP600125) and small interfering RNA (siRNA)-mediated down-regulation of JNK led to a reduction of iNOS mRNA and protein expression. iNOS promoter activity was not affected by these treatments. Hence, JNK seems to regulate iNOS expression through post-transcriptional mechanisms by stabilizing iNOS mRNA. Our labo…

Small interfering RNARNA Stabilityp38 mitogen-activated protein kinasesDown-RegulationNitric Oxide Synthase Type IIRNA-binding proteinNitric Oxidep38 Mitogen-Activated Protein KinasesGene Expression Regulation EnzymologicCell LineTristetraprolinHumansPhosphorylationRNA Small InterferingPromoter Regions GeneticPost-transcriptional regulationAnthracenesPharmacologyRegulation of gene expressionMessenger RNAbiologyChemistryKinaseJNK Mitogen-Activated Protein KinasesEpithelial Cellsrespiratory systemMolecular biologyPulmonary AlveoliNitric oxide synthasebiology.proteinCytokinesMolecular MedicineSignal TransductionMolecular Pharmacology
researchProduct

Response of yeast cells to high glucose involves molecular and physiological differences when compared to other osmostress conditions.

2015

Yeast cells can be affected by several causes of osmotic stress, such as high salt, sorbitol or glucose concentrations. The last condition is particularly interesting during natural processes where this microorganism participates. Response to osmostress requires the HOG (High Osmolarity Glycerol) pathway and several transcription factors, including Hot1, which plays a key role in high glucose concentrations. In this work, we describe how the yeast response to osmotic stress shows differences in accordance with the stress agent responsible for it. Compared with other conditions, under high glucose stress, delocalization of MAPK (Mitogen-Activated Protein Kinase) Hog1 is slower, induction of …

Snf3Saccharomyces cerevisiae ProteinsOsmotic shockTranscription GeneticSaccharomyces cerevisiaeChitinSaccharomyces cerevisiaeOsmosisApplied Microbiology and BiotechnologyMicrobiologychemistry.chemical_compoundOsmotic PressureGene Expression Regulation FungalSorbitolProtein kinase AbiologyGlycogenEthanolBenzenesulfonatesOsmolar ConcentrationGeneral Medicinebiology.organism_classificationYeastDNA-Binding ProteinsRepressor ProteinsBasic-Leucine Zipper Transcription FactorsGlucosechemistryBiochemistrySorbitolMitogen-Activated Protein KinasesTranscription FactorsFEMS yeast research
researchProduct

Molecular mechanisms of sorafenib action in liver cancer cells.

2012

Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced hepatocellular carcinoma (HCC). However, as the clinical application of sorafenib evolves, there is increasing interest in defining the mechanisms underlying its anti-tumor activity. Considering that this specific inhibitor could target unexpected molecules depending on the biologic context, a precise understanding of its mechanism of action could be critical to maximize its treatment efficacy, while minimizing adverse effects. Two human HCC cell lines (HepG2 and Huh7), carrying different biological and genetic characteristics, were used in this study to examine the intracellular events leading …

SorafenibDNA ReplicationNiacinamideCarcinoma HepatocellularDNA RepairTranscription GeneticAngiogenesisCell SurvivalPyridinesApoptosisPharmacologyBiologysorafenib HCC mini-chromosome maintenance genes Dickkopf1 Harakiri Acheron/LARP6 YAP1 cell cycle microarray global gene expression analysisCell Line TumormedicineCell AdhesionHumansneoplasmsMolecular BiologyProtein Kinase InhibitorsCell ProliferationYAP1Neovascularization PathologicCell growthGene Expression ProfilingPhenylurea CompoundsBenzenesulfonatesCell CycleLiver NeoplasmsBiological TransportCell BiologyCell cycleSorafenibmedicine.diseasedigestive system diseasesMechanism of actionHepatocellular carcinomaProtein Biosynthesismedicine.symptomMitogen-Activated Protein KinasesLiver cancerDevelopmental Biologymedicine.drugSignal Transduction
researchProduct

BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.

2013

Abstract: Introduction: Several new targeted agents with anti-angiogenic properties have been developed recently, including vandetanib, sunitinib, sorafenib, bevacizumab and others. Tumor development, progression, metastasis are strongly linked to angiogenesis. Targeted agents like bevacizumab, a monoclonal antibody which targets VEGF, have been fully developed in several solid tumors. These new agents strongly advocate that targeting angiogenesis is one of the best approaches for cancer therapy. Areas covered: Those agents that target additional pro-angiogenic intracellular signaling pathways beyond VEGF signaling have also the potential to contribute to anticancer therapies. The authors p…

SorafenibIndolesLung NeoplasmsBevacizumabSettore MED/06 - Oncologia MedicaAngiogenesis InhibitorsPharmacologyVandetanibMetastasischemistry.chemical_compoundCarcinoma Non-Small-Cell LungmedicineAnimalsHumansPharmacology (medical)Lung cancerProtein Kinase InhibitorsPharmacologyNeovascularization Pathologicbusiness.industrySunitinibPharmacology. Therapyanti-angiogenesis BIBF 1120 nintedanib non-small cell lung cancer vascular endothelial growth factorGeneral MedicineProtein-Tyrosine Kinasesmedicine.diseaseVascular endothelial growth factorchemistryCancer researchNintedanibbusinessmedicine.drugExpert opinion on investigational drugs
researchProduct

Sorafenib in advanced hepatocellular carcinoma

2008

none 25 BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Seconda…

SorafenibMaleNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularPyridinesPlaceboGastroenterologyDouble-Blind MethodInternal medicinemedicineCarcinomaHumansHEPATOCELLULAR CARCINOMAProtein Kinase InhibitorsAgedNeoplasm StagingProportional Hazards Modelsbusiness.industryPhenylurea CompoundsHazard ratioBenzenesulfonatesLiver NeoplasmsGeneral MedicineTREATMENTMiddle AgedSorafenibmedicine.diseaseInterim analysisSurvival AnalysisRecurrent Hepatocellular Carcinomadigestive system diseasesSurgeryHEPATOCELLULAR CARCINOMA; SORAFENIB; TREATMENTChemotherapy AdjuvantHepatocellular carcinomaDisease ProgressionFemaleraf KinasesbusinessLiver cancermedicine.drug
researchProduct

Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy

2015

Abstract: Introduction: Angiogenesis is fundamental for tumor development and progression. Hence, anti-angiogenic drugs have been developed to target VEGF and its receptors (VEGFRs). Several tyrosine kinase inhibitors (TKIs) have been developed over the years and others are still under investigation, each anti-VEGFR TKI showing a different cardiotoxic profile. Knowledge of the cardiac side-effects of each drug and the magnitude of their expression and frequency can lead to a specific approach. Areas covered: This work reviews the mechanism of action of anti-VEGFR TKIs and the pathophysiological mechanisms leading to cardiotoxicity, followed by close examination of the most important drugs i…

SorafenibOncologymedicine.medical_specialtymedicine.drug_classSettore MED/06 - Oncologia MedicaAntineoplastic AgentsPharmacologyVandetanibModels BiologicalTyrosine-kinase inhibitorPazopanibchemistry.chemical_compoundInternal medicineRegorafenibNeoplasmsmedicineHumansPharmacology (medical)Molecular Targeted TherapyProtein Kinase Inhibitorstyrosine kinase inhibitor cardiac toxicityNeovascularization PathologicSunitinibbusiness.industryPharmacology. TherapyCancerHeartGeneral MedicineDrugs InvestigationalProtein-Tyrosine Kinasesmedicine.diseaseAxitinibReceptors Vascular Endothelial Growth FactorchemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

p38 MAPK activation is required for Paracentrotus lividus skeletogenesis

2008

We investigated the p38 MAPK role during sea urchin, Paracentrotus lividus, development. We found that at the morula stage, before the onset of skeletogenesis, p38 MAPK shows a peak of activity, and we tested whether p38 MAPK activity has any effect on skeletogenesis. By immunohistochemistry on whole-mount embryos we show the preferential localization of the active p38 form both in the presumptive PMCs and bilateral spiculo- genesis centers in control embryos, and in the radialized supernumerary spiculogenesis centers induced by NiCl2 treatment. By using SB203580, a p38 MAPK specific inhibitor, we show that p38 activity is required both for the initial triradiate spicule rudiments formation…

Spiculeanimal structuresbiologyp38 mitogen-activated protein kinasesEmbryoAnatomyp38 MAPKbiology.organism_classificationSB203580Paracentrotus lividusCell biologyskeletogenesissea urchin developmentbiology.animalembryonic structuresGeneticsImmunohistochemistryp38 MAPK; SB203580; sea urchin development; skeletogenesisGeneral Agricultural and Biological SciencesSea urchin
researchProduct

Comprehensive estimation of input signals and dynamics in biochemical reaction networks

2012

Abstract Motivation: Cellular information processing can be described mathematically using differential equations. Often, external stimulation of cells by compounds such as drugs or hormones leading to activation has to be considered. Mathematically, the stimulus is represented by a time-dependent input function. Parameters such as rate constants of the molecular interactions are often unknown and need to be estimated from experimental data, e.g. by maximum likelihood estimation. For this purpose, the input function has to be defined for all times of the integration interval. This is usually achieved by approximating the input by interpolation or smoothing of the measured data. This procedu…

Statistics and ProbabilityMedicin och hälsovetenskapComputer scienceDifferential equationMaximum likelihoodcomputer.software_genreBiochemistryModels BiologicalMedical and Health SciencesIntegration intervalMolecular BiologyJanus KinasesLikelihood FunctionsRegulation Pathways and Systems BiologyExperimental dataOriginal PapersConfidence intervalComputer Science ApplicationsComputational MathematicsSTAT Transcription FactorsComputational Theory and MathematicsData miningAlgorithmcomputerSmoothingAlgorithmsSignal Transduction
researchProduct